Followers

July 20, 2024

Jubilant Pharmova posts multi-fold rise in Q1 net profit to Rs 481.8 cr

​The exceptional items in the first quarter of the current fiscal include net income of Rs 669.2 crore following sale of investment in SOFIE, expenses of Rs 91.6 crore accrued due to closure of manufacturing operations of solid dosage formulation facility at Salisbury, Maryland, USA; Rs 95.3 crore provision for slow moving inventory in respect of solid dosage formulation business and litigation cost of Rs 50 crore among others.

from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/nqPaJMW

No comments:

Post a Comment